Figure 1: Synthetic lethality to paclitaxel + RTK inhibitor in endometrial cancer cells requires loss of functional p53. Hec50 endometrial cancer cells which are p53-null were transfected with either WT p53 or GOF p53 mutant R175H, one of the most commonly observed p53 GOF mutations in cancer. (a) Expression of p53 in Hec50 cells by Western blotting. (b) Percentage of mitotic cells after treatment with paclitaxel (10 nM) and/or EGFR inhibitor gefitinib (10 μM) for 24 h.